Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Immunomedics, UCB recruit first patient in Embody 1, 2 studies
Immunomedics and UCB said that each study will will randomise 780 subjects in the study, with approximately 130 planned investigational sites per study. The primary objective of the
Immunomedics and UCB said that each study will will randomise 780 subjects in the study, with approximately 130 planned investigational sites per study. The primary objective of the
FDA has advised that the consumers who have Man Up Now capsules should stop using them immediately. Synergy Distribution claims that Man Up Now is ‘herbal’ and ‘all
Lilly, in consultation with an independent data monitoring committee, recommended a ‘full clinical hold,’ because of safety concerns. Following the declaration of clinical hold no new or existing
Amgen has evaluated XGEVA (denosumab) versus placebo in 1,432 men with castrate-resistant prostate cancer in ‘147 study Phase 3 trial. In the trial, the overall survival was similar
Inimex Pharma claims IMX942 is the first of a new class of drugs known as Innate Defense Regulators (IDRs), which improve survival, ameliorate tissue damage and reduce bacterial
Garabedian has been vice president of corporate strategy at Celgene Corporation since July 2007 ans was responsible for Celgene’s strategic and financial plan and supported the executive management
The platforms will provide improvements in clinical study timelines by accelerating data acquisition and the processing of final client reports in its Phase I clinics. PharmaNet, with the
McNeil Consumer Healthcare informed Health Canada that they are taking this action following consumer reports of foreign materials in the product, including metal and wood particles. McNeil is
In each case, the filing of the application will initiate an undisclosed milestone payment to MorphoSys. The therapeutic antibodies are being developed in the therapeutic areas of cancer
Administered every six months as a convenient subcutaneous injection, Denosumab reduces the risk of fractures at the spine, hip and other key non-vertebral sites. Amgen and GSK said